

From: [Oliver Knott](#)
To: [Michael Carroll](#)
Cc: [Gregory Perry](#); [Geoff Wallace](#)
Subject: RE: Monthly Epidiolex accountability spreadsheet for August 2017
Date: Friday, 1 September 2017 8:31:33 PM
Attachments: [image001.png](#)
[image002.png](#)
[image003.png](#)
[image004.png](#)
[image005.png](#)

Thanks very much Michael.

Kind regards,

Oliver

From: Michael Carroll [mailto:Michael.Carroll@health.qld.gov.au]
Sent: 01 September 2017 07:38
To: Oliver Knott
Cc: Gregory Perry; Geoff Wallace
Subject: RE: Monthly Epidiolex accountability spreadsheet for August 2017

Hi Oliver,

The data spreadsheets aren't entirely up to date so I have attached their current versions for your information. While there's only a small amount of work to go, these versions will, in the interim, inform on AE information to date.

Please let me know if you have any questions.

Kind regards,

Michael Carroll
Clinical Research Manager (Neurodevelopmental Disorders)

Children's Health Queensland Hospital and Health Service
Level 6 – Centre for Children's Health Research
Lady Cilento Children's Hospital
62 Graham Street, South Brisbane QLD 4101

T: +61 7 3069 7405 M: [\[redacted\]](#)
E: Michael.Carroll@health.qld.gov.au
W: www.childrens.health.qld.gov.au



Children's Health Queensland

Service | Integrity | Courage | Innovation | Accountability

Queensland Health acknowledges the Traditional Owners of the land, and pays respect to Elders past, present and future.

From: Oliver Knott [mailto:[\[redacted\]@gwpharm.com](mailto:[redacted]@gwpharm.com)]
Sent: Thursday, 31 August 2017 9:01 PM
To: Michael Carroll
Cc: Gregory Perry
Subject: RE: Monthly Epidiolex accountability spreadsheet for August 2017

Thanks Michael.

From: Michael Carroll [<mailto:Michael.Carroll@health.qld.gov.au>]
Sent: 31 August 2017 07:56
To: Oliver Knott
Cc: Gregory Perry
Subject: Monthly Epidiolex accountability spreadsheet for August 2017

Hi Oliver,

Please find attached our monthly Epidiolex accountability spreadsheet for August 2017.

The monthly data backlog is progressing however if it's not completed tomorrow I'll send you an update on AE information.

Kind regards,

Michael Carroll
Clinical Research Manager (Neurodevelopmental Disorders)
Children's Health Queensland Hospital and Health Service
Level 6 – Centre for Children's Health Research
Lady Cilento Children's Hospital
62 Graham Street, South Brisbane QLD 4101

T: +61 7 3069 7405 M:
E: Michael.Carroll@health.qld.gov.au
W: www.childrens.health.qld.gov.au



Children's Health Queensland

Service | Integrity | Courage | Innovation | Accountability

Queensland Health acknowledges the Traditional Owners of the land, and pays respect to Elders past, present and future.

This email, including any attachments sent with it, is confidential and for the sole use of the intended recipient(s). This confidentiality is not waived or lost, if you receive it and you are not the intended recipient(s), or if it is transmitted/received in error.

Any unauthorised use, alteration, disclosure, distribution or review of this email is strictly prohibited. The information contained in this email, including any attachments sent with it, may be subject to a statutory duty of confidentiality if it relates to health service matters.

If you are not the intended recipient(s), or if you have received this email in error, you are asked to immediately notify the sender by telephone collect on Australia +61 1800 198 175 or by return email. You should also delete this email, and any copies, from your computer system network and destroy any hard copies produced.

If not an intended recipient of this email, you must not copy, distribute or take any action(s) that relies on it; any form of disclosure, modification, distribution and/or publication of this email is also prohibited.

Although Queensland Health takes all reasonable steps to ensure this email does not contain malicious software, Queensland Health does not accept responsibility for the consequences if any person's computer inadvertently suffers any disruption to services, loss of information, harm or is infected with a virus, other malicious computer programme or code that may occur as a consequence of receiving this email.

Unless stated otherwise, this email represents only the views of the sender and not the views of the Queensland Government.

PLEASE READ: This email is confidential and may be privileged. It is intended for the

named addressee(s) only and access to it by anyone else is unauthorised. If you are not an addressee, any disclosure or copying of the contents of this email or any action taken (or not taken) in reliance on it is unauthorised and may be unlawful. If you have received this email in error, please notify the sender or postmaster@gwpharm.com Email is not a secure method of communication and the Company cannot accept responsibility for the accuracy or completeness of this message or any attachment(s). Please check this email for virus infection for which the Company accepts no responsibility. If verification of this email is sought then please request a hard copy. Unless otherwise stated, any views or opinions presented are solely those of the author and do not represent those of the Company.

RTI Release

From: [Michael Carroll](#)
To: [Oliver Knott](#)
Cc: [Gregory Perry](#); [Geoff Wallace](#)
Subject: RE: Monthly Epidiolex accountability spreadsheet for August 2017
Date: Friday, 1 September 2017 4:38:40 PM
Attachments: [image001.png](#)
[image002.png](#)
[image003.png](#)
[image004.png](#)
[image005.png](#)
[Epidiolex Spreadsheet OLD Patients 11 20 year 1 to AUGUST - Incomplete.xls](#)
[Epidiolex Spreadsheet OLD Patients 1 10 year 1 to AUGUST - Incomplete.xls](#)

Hi Oliver,

The data spreadsheets aren't entirely up to date so I have attached their current versions for your information. While there's only a small amount of work to go, these versions will, in the interim, inform on AE information to date.

Please let me know if you have any questions.

Kind regards,

Michael Carroll

Clinical Research Manager (Neurodevelopmental Disorders)

Children's Health Queensland Hospital and Health Service
Level 6 – Centre for Children's Health Research
Lady Cilento Children's Hospital
62 Graham Street, South Brisbane QLD 4101

T: +61 7 3069 7405 M:

E: Michael.Carroll@health.qld.gov.au

W: www.childrens.health.qld.gov.au



Children's Health Queensland

Service | Integrity | Courage | Innovation | Accountability

Queensland Health acknowledges the Traditional Owners of the land, and pays respect to Elders past, present and future.

From: Oliver Knott [mailto:@gwpharm.com]
Sent: Thursday, 31 August 2017 9:01 PM
To: Michael Carroll
Cc: Gregory Perry
Subject: RE: Monthly Epidiolex accountability spreadsheet for August 2017

Thanks Michael.

From: Michael Carroll [mailto:Michael.Carroll@health.qld.gov.au]
Sent: 31 August 2017 07:56
To: Oliver Knott
Cc: Gregory Perry
Subject: Monthly Epidiolex accountability spreadsheet for August 2017

Hi Oliver,

Please find attached our monthly Epidiolex accountability spreadsheet for August 2017.

The monthly data backlog is progressing however if it's not completed tomorrow I'll send you an update on AE information.

Kind regards,

Michael Carroll

Clinical Research Manager (Neurodevelopmental Disorders)

Children's Health Queensland Hospital and Health Service

Level 6 – Centre for Children's Health Research

Lady Cilento Children's Hospital

62 Graham Street, South Brisbane QLD 4101

T: +61 7 3069 7405 M:

E: Michael.Carroll@health.qld.gov.au

W: www.childrens.health.qld.gov.au



Queensland Health acknowledges the Traditional Owners of the land, and pays respect to Elders past, present and future.

This email, including any attachments sent with it, is confidential and for the sole use of the intended recipient(s). This confidentiality is not waived or lost, if you receive it and you are not the intended recipient(s), or if it is transmitted/received in error.

Any unauthorised use, alteration, disclosure, distribution or review of this email is strictly prohibited. The information contained in this email, including any attachment sent with it, may be subject to a statutory duty of confidentiality if it relates to health service matters.

If you are not the intended recipient(s), or if you have received this email in error, you are asked to immediately notify the sender by telephone collect on Australia +61 1800 198 172 or by return email. You should also delete this email, and any copies, from your computer system network and destroy any hard copies produced.

If not an intended recipient of this email, you must not copy, distribute or take any action(s) that relies on it; any form of disclosure, modification, distribution and/or publication of this email is also prohibited.

Although Queensland Health takes all reasonable steps to ensure this email does not contain malicious software, Queensland Health does not accept responsibility for the consequences if any person's computer inadvertently suffers any disruption to services, loss of information, harm or is infected with a virus, other malicious computer programme or code that may occur as a consequence of receiving this email.

Unless stated otherwise, this email represents only the views of the sender and not the views of the Queensland Government.

PLEASE READ: This email is confidential and may be privileged. It is intended for the named addressee(s) only and access to it by anyone else is unauthorised. If you are not an addressee, any disclosure or copying of the contents of this email or any action taken (or not taken) in reliance on it is unauthorised and may be unlawful. If you have received this email in error, please notify the sender or postmaster@gwpharm.com Email is not a secure method of communication and the Company cannot accept responsibility for the accuracy or completeness of this message or any attachment(s). Please check this email for virus infection for which the Company accepts no responsibility. If verification of this email is sought then please request a hard copy. Unless otherwise stated, any views or opinions presented are solely those of the author and do not represent those of the Company.

From: [Michael Carroll](#)
To: [Oliver Knott](#)
Cc: [Gregory Perry](#)
Subject: Monthly Epidiolex accountability spreadsheet for August 2017
Date: Thursday, 31 August 2017 4:56:08 PM
Attachments: [image001.png](#)
[image002.png](#)
[image003.png](#)
[image004.png](#)
[image005.png](#)
[Monthly Epidiolex accountability spreadsheet AUGUST 2017.xls](#)

Hi Oliver,

Please find attached our monthly Epidiolex accountability spreadsheet for August 2017.

The monthly data backlog is progressing however if it's not completed tomorrow I'll send you an update on AE information.

Kind regards,

Michael Carroll

Clinical Research Manager (Neurodevelopmental Disorders)

Children's Health Queensland Hospital and Health Service

Level 6 – Centre for Children's Health Research

Lady Cilento Children's Hospital

62 Graham Street, South Brisbane QLD 4101

T: +61 7 3069 7405 M:

E: Michael.Carroll@health.qld.gov.au

W: www.childrens.health.qld.gov.au



Children's Health Queensland

Service | Integrity | Courage | Innovation | Accountability

Queensland Health acknowledges the Traditional Owners of the land, and pays respect to Elders past, present and future.

RTI Release

Year: 2017

Epidiolex accountability - numbers of 100ml bottles of Epidiolex

Item	January	February	March	April	May	June	July	August	September	October	November	December
Date of end-of-month stock review		28/02/2017	31/03/2017	28/04/2017	29/05/2017	29/06/2017	25/07/2017	29/08/2017				
Central Pharmacy:												
Stock held at start of month	0 bottles	226 bottles	196 bottles	188 bottles	172 bottles	140 bottles	100 bottles	76 bottles				
Stock received from GWP	226 bottles	0 bottles	0 bottles	0 bottles	0 bottles	0 bottles	0 bottles	0 bottles				
Stock transferred to LCCH Pharmacy	0 bottles	30 bottles	8 bottles	16 bottles	32 bottles	40 bottles	24 bottles	76 bottles				
Stock held at end of month	226 bottles	196 bottles	188 bottles	172 bottles	140 bottles	100 bottles	76 bottles	0 bottles **				
LCCH Pharmacy:												
Stock held at start of month	0 bottles	0 bottles	28 bottles	25 bottles	32 bottles	43 bottles	45 bottles	31 bottles				
Stock received from Central Pharmacy	0 bottles	30 bottles	8 bottles	16 bottles	32 bottles	40 bottles	24 bottles	76 bottles				
Stock dispensed to patients	0 bottles	2 bottles	11 bottles	9 bottles	21 bottles	38 bottles	38 bottles	74 bottles				
Stock at end of month	0 bottles	28 bottles	25 bottles	32 bottles	43 bottles	45 bottles	31 bottles	33 bottles				
Stock held by Authorised Prescribers	0 bottles	0 bottles	0 bottles	0 bottles	0 bottles	0 bottles	0 bottles	0 bottles				
Unused product returned by participants	0 bottles	0 bottles	0 bottles	0 bottles	0 bottles	0 bottles	0 bottles	0 bottles				

**Note: most patients have enough stock dispensed to last through until end of September - more stock has been ordered (Rochelle Green)

RTI Release

From: [Gregory Perry](#)
To: [Oliver Knott](#)
Cc: [Michael Carroll](#); [Rochelle Green](#)
Subject: Re: Future syringe orders for CAS
Date: Wednesday, 30 August 2017 6:33:53 AM

Thanks Oliver we will do that for future orders

Greg

Sent from my iPhone

On 30 Aug 2017, at 12:57 am, Oliver Knott <[\[redacted\]@gwpharm.com](#)> wrote:

Hi Greg / Michael,

For future orders of syringes that you need please can you complete the attached?

The other order form still needs to be completed but will only have details of the IMP order requirements.

Many thanks,

Oliver

Oliver Knott | Clinical Project Manager



<image001.jpg>

Sovereign House, Vision Park, Chivers Way, Histon, Cambridge CB24 9BZ, UK | Tel: [\[redacted\]](#)



www.gwpharm.com

PLEASE READ: This email is confidential and may be privileged. It is intended for the named addressee(s) only and access to it by anyone else is unauthorised. If you are not an addressee, any disclosure or copying of the contents of this email or any action taken (or not taken) in reliance on it is unauthorised and may be unlawful. If you have received this email in error, please notify the sender or postmaster@gwpharm.com. Email is not a secure method of communication and the Company cannot accept responsibility for the accuracy or completeness of this message or any attachment(s). Please check this email for virus infection for which the Company accepts no responsibility. If verification of this email is sought then please request a hard copy. Unless otherwise stated, any views or opinions presented are solely those of the author and do not represent those of the Company.

<CT-GMP-229-V1 Syring Shipment Request Form (Current Version as of 24 Aug17).dotx>

RTI Release

From: Gregory Perry
To: Louise Harris
Cc: Oliver Knott
Subject: Re: Epidiolex order
Date: Wednesday, 30 August 2017 6:31:17 AM

Yes Louise that was really fast! Thanks very much
Greg

Sent from my iPhone

On 29 Aug 2017, at 6:51 pm, Louise Harris <[redacted]@gwpharm.com> wrote:

Great thanks Greg!

That was quick. I hope that was timely enough for yourselves as well.

cc. Oli - FYI only

KR,

Louise Harris | IPS Programme Manager

[redacted]

G-Pharm

Kent Science Park, Sittingbourne, Kent, ME9 8AG, UK

[redacted]

Upcoming OOO:

UK BH – Mon 28th Aug 2017

Fri 1st Sep 2017

Wed 13th – Fri 15th Sep 2017 (inc.)

Upcoming BH:

28th Aug 2017

From: Gregory Perry [mailto:Gregory.Perry@health.qld.gov.au]

Sent: 29 August 2017 07:18

To: Louise Harris

Subject: FW: Epidiolex order

Please ignore my last email! – its arrived in [redacted]

greg

From: [redacted]@linkhealthcare.com.au]

Sent: Tuesday, 29 August 2017 4:16 PM

To: Rochelle Green

Cc: Michael Carroll; Gregory Perry

Subject: RE: Epidiolex order

Hi Rochelle

The product has arrived in [redacted] and is being processed through customs. We hope to have delivery tomorrow.

I will confirm once goods have been delivered and released by quality.

Thanks

[redacted]
Supply Chain Manager

Link Healthcare

T [redacted]
M [redacted]
E [redacted]
W www.clinigengroup.com

<image001.png>

Registered Office: Clinigen Group plc, Pitcairn House, Crown Square, Centrum 100 Burton-on-Trent, Staffordshire, DE14 2WW Registered In England & Wales No.06771928

This email may be confidential and/or privileged. Only the intended recipient may access or use it. If you are not the intended recipient, please delete this email and notify us promptly. We use virus scanning software but exclude all liability for viruses or similar in any attachment.

From: Rochelle Green [<mailto:Rochelle.Green@health.qld.gov.au>]

Sent: Tuesday, 29 August 2017 3:56 PM

To: [redacted]@linkhealthcare.com.au>

Cc: Michael Carroll <Michael.Carroll@health.qld.gov.au>; Gregory Perry <Gregory.Perry@health.qld.gov.au>

Subject: Epidiolex order

Hi [redacted]

can I please check how things are progressing with the order discussed below. More specifically has the order been shipped yet?

Many thanks,
Rochelle

Rochelle Green

Senior Pharmacist - Neurodevelopmental Disorders and Clinical Trials

Lady Cilento Children's Hospital
501 Stanley Street South Brisbane
QLD 4101

T: 3068 1913

E: rochelle.green@health.qld.gov.au

From: Gregory Perry

Sent: Thursday, 24 August 2017 8:16 AM

To: [redacted]@linkhealthcare.com.au)
Cc: [redacted]@gwpharm.com; Louise Blatchford; Graham Cook; Michael Carroll; Rochelle Green; MCTeam
Subject: increased order

Hi [redacted] and all, at the meeting between QH and GW yesterday, it was advised that we could increase the order for Epidiolex this time up to 150 packs (300 bottles)

Apparently the import permit issued and received by GW is for this figure – because our stocks are running low it would be good to have this stock on its way as soon as possible.

Louise, as requested I have changed the delivery address to reflect the Link healthcare warehouse and have changed the contact to [redacted] at Link

Kind regards
Greg
<image002.png>

Gregory Perry
Director
Medicinal Cannabis Unit
Chief Medical Officer and Healthcare Regulation Branch
Prevention Division, **Department of Health**
p: 07 3708 5316 | m: [redacted]
a: Locked Bag 21, Fortitude Valley BC QLD 4006
w: Queensland Health | e: Gregory.Perry@health.qld.gov.au
<image003.jpg> <image004.jpg> <image005.jpg> <image006.jpg>

Queensland's health vision | By 2026 Queenslanders will be among the healthiest people in the world.

Queensland Health acknowledges the Traditional Owners of the land, and pays respect to Elders past, present and future.

This email, including any attachments sent with it, is confidential and for the sole use of the intended recipient(s). This confidentiality is not waived or lost, if you receive it and you are not the intended recipient(s), or if it is transmitted/received in error.

Any unauthorised use, alteration, disclosure, distribution or review of this email is strictly prohibited. The information contained in this email, including any attachment sent with it, may be subject to a statutory duty of confidentiality if it relates to health service matters.

If you are not the intended recipient(s), or if you have received this email in error, you are asked to immediately notify the sender by telephone collect on Australia +61 1800 198 175 or by return email. You should also delete this email, and any copies, from your computer system network and destroy any hard copies produced.

If not an intended recipient of this email, you must not copy, distribute or take any action(s) that relies on it; any form of disclosure, modification, distribution and/or publication of this email is also prohibited.

Although Queensland Health takes all reasonable steps to ensure this email does not contain malicious software, Queensland Health does not accept responsibility for the consequences if any person's computer inadvertently suffers any disruption to services, loss of information, harm or is infected with a virus, other malicious computer programme or code that may occur as a consequence of receiving this email.

Unless stated otherwise, this email represents only the views of the sender and not the views of the Queensland Government.

PLEASE READ: This email is confidential and may be privileged. It is intended for the named addressee(s) only and access to it by anyone else is unauthorised. If you are not an addressee, any disclosure or copying of the contents of this email or any action taken (or not taken) in reliance on it is unauthorised and may be unlawful. If you have received this email in error, please notify the sender or postmaster@gwpharm.com. Email is not a secure method of communication and the Company cannot accept responsibility for the accuracy or completeness of this message or any attachment(s). Please check this email for virus infection for which the Company accepts no responsibility. If verification of this email is sought then please request a hard copy. Unless otherwise stated, any views or opinions presented are solely those of the author and do not represent those of the Company.

RTI Released

From: [Oliver Knott](#)
To: [Gregory Perry](#); [Michael Carroll](#)
Subject: Future syringe orders for CAS
Date: Wednesday, 30 August 2017 12:57:40 AM
Attachments: [CT-GMP-229-V1 Syringe Shipment Request Form \(Current Version as of 24 Aug17\).dotx](#)

Hi Greg / Michael,

For future orders of syringes that you need please can you complete the attached?


The other order form still needs to be completed but will only have details of the IMP order requirements.

Many thanks,

Oliver

Oliver Knott | Clinical Project Manager



Sovereign House, Vision Park, Chivers Way, Histon, Cambridge CB24 9BZ, UK | Tel: 
www.gwpharm.com

PLEASE READ: This email is confidential and may be privileged. It is intended for the named addressee(s) only and access to it by anyone else is unauthorised. If you are not an addressee, any disclosure or copying of the contents of this email or any action taken (or not taken) in reliance on it is unauthorised and may be unlawful. If you have received this email in error, please notify the sender or postmaster@gwpharm.com Email is not a secure method of communication and the Company cannot accept responsibility for the accuracy or completeness of this message or any attachment(s). Please check this email for virus infection for which the Company accepts no responsibility. If verification of this email is sought then please request a hard copy. Unless otherwise stated, any views or opinions presented are solely those of the author and do not represent those of the Company.

Order No:
(to be completed by Distribution Group)

Syringe Shipment Request Form

SECTION 1: Trial and Site details:

Study Number:		Site Number:	
Site CRA Name:		Date Required:	
Investigator Name:			

SECTION 2: Syringe requirement:

Item Code	Product Description	No. of packs (MOQ 1 pack = 50 units)
MA0188 & MA0161	Amber 1mL Oral Syringe and Bottle Adapter (study specific, subject to approval by Distribution Group)	
MA0160	Clear 5mL Oral Syringe & Bottle Adapter	
MA0165	Clear 10mL Oral Syringe & Bottle Adapter	
MA0189	Amber 5mL Oral Syringe & Bottle Adapter	
MA0208	Amber 10mL Oral Syringe & Bottle Adapter	

SECTION 3: Despatch Details

Recipient Name:		
Site / Pharmacy Name:		
Address:	Building Number & Street:	
	Town/City:	
	State/Province/County:	
	Postcode/Zip code:	
	Country:	
Tel:		
Email:		

SECTION 4: Requestor Details

Printed Name:		
Signature:		Date:
Notes:		

SECTION 5: Shipment Details (to be completed by Distribution Group)

Processed By (name):		Shipment Date:	
Signature:		Courier Reference Number:	

Email to: @g-pharm.com

From: Rochelle Green
To: Gregory Perry
Subject: RE: CBD for aDravet's patient
Date: Tuesday, 29 August 2017 9:32:13 AM

Thanks Greg!

Rochelle Green

Senior Pharmacist - Neurodevelopmental Disorders and Clinical Trials

Lady Cilento Children's Hospital
501 Stanley Street South Brisbane
QLD 4101

T: 3068 1913
E: rochelle.green@health.qld.gov.au

From: Gregory Perry
Sent: Tuesday, 29 August 2017 8:44 AM
To: Rochelle Green
Subject: RE: CBD for aDravet's patient

[redacted] contacted me to ask how we could access stock and what paperwork was required to prescribe CBD in a patient with Dravet's for seizure control.

[redacted] is already an Approved prescriber through the TGA and as this is for seizures we would be using the approved prescriber pathway. The approved prescriber status with the TGA relates only to Epidiolex under the protocol for the CAS. So any other product would need to be through a SAS B application to TGA - [redacted] will have a patient class prescriber status in Qld so will not requires a Qld approval from the DG only notification to the DG within 7 days of commencing.

I'm assuming we won't be able to get GW product for this so was considering Tilray CBD 100mg/mL liquid. My understanding is that [redacted] would just need a SAS Cat B form to access a Tilray product. Can I just check that I'm on the right track here and not telling the poor doctor the wrong thing??

That's right Epidiolex is not yet available outside the trial. Yes will be SAS Cat B application - form attached - Also form for PCP in QLD form attached

Also have a look at this site to see what is available <https://cannabisaccess.com.au/home>

Cannabidiol (CBD) 100 mg per mL in a Purified Formulation of Cannabis Extract delivered as an Oral Solution. Active Ingredient Purity: >98% Purified Oral Solution. Products: active ingredients in different THC and CBD strengths/ratios, shown in mg/mL. Format: 25 mL bottle with 1 mL dropper cap dispenser Formulation: Liquid oil. Excipients: Grapeseed oil. Product classification specifications: Active Ingredient Purity = >98% Minor Cannabinoid Presence = <1.0% Other = <0.15% each, <1.0% total. Packaging and Storage Information: Package Size = 11.5cm x 3.4cm Package Weight = 30 g. Storage Conditions = +2° to +8° C Expiry = 12 months. Indications & Usage: Use as prescribed.

Greg

From: Rochelle Green
Sent: Monday, 28 August 2017 4:46 PM
To: Gregory Perry
Subject: CBD for aDravet's patient

Hi Greg,

hope you had a great weekend. Andrew Hallahan may have already contacted you about this (sorry if I'm repeating the same questions!).

[redacted] contacted me to ask how we could access stock and what paperwork was required to prescribe CBD in a patient with Dravet's for seizure control.

[redacted] is already an Approved prescriber through the TGA and as this is for seizures we would be using the approved prescriber pathway.

I'm assuming we won't be able to get GW product for this so was considering Tilray CBD 100mg/mL liquid. My understanding is that [redacted] would just need a SAS Cat B form to access a Tilray product. Can I just check that I'm on the right track here and not telling the poor doctor the wrong thing??

Thanks!
Rochelle

Rochelle Green

Senior Pharmacist - Neurodevelopmental Disorders and Clinical Trials

Lady Cilento Children's Hospital
501 Stanley Street South Brisbane
QLD 4101

T: 3068 1913
E: rochelle.green@health.qld.gov.au

RTI Release



This form, when completed, will be classified as 'For official use only'.
 For guidance on how your information will be treated by the TGA see: Treatment of information provided to the TGA at
<http://www.tga.gov.au/about/tga-information-to.htm>.

Category B form Special Access Scheme

Please complete clearly and in full - forms cannot be processed if incomplete or illegible

Do not provide the name of the patient. Only provide the patient's initials and other information as requested on this form.
 Email completed form to SAS@tga.gov.au (preferred) or fax to 02 6232 8112.

Privacy information

For general privacy information, go to <http://www.tga.gov.au/about/website-privacy.htm>.

The TGA is collecting personal information in this form in order to:

- Assess the application.
- Contact the medical practitioner and discuss the application where necessary.
- The personal information of the medical practitioner may be disclosed to State and Territory authorities with responsibility for therapeutic goods or medical practitioner registration.

Patient details (minimum of 3 (three) identifiers required)

Patient's initials		DOB	
MRN (if applicable)		Gender	
Diagnosis		Previous SAS No. (if applicable)	
Clinical justification for use of product. For example - Include seriousness of condition, details of previous treatment			

Product details

*Attach efficacy and safety data to support proposed use of the product and details of intended monitoring. Note: Boxes marked with an * must be completed for devices.*

Active ingredient		Trade name/device name*	
Company/supplier*		Route of administration	
Dose form & strength (e.g. 500mg tablet)		Proposed treatment duration	
Dose & frequency* (e.g. 1 tds)			
Intended date of use*		Proposed quantity*	

Prescriber details

Name		Pharmacy fax	
Hospital/department		OR Doctor fax	
Postal address		Phone	
		Email	

Please note that the giving of false or misleading information is an offence under Criminal Code Act 1995 and that penalties may be imposed

Prescriber signature		Date	
----------------------	--	------	--



Queensland Health
Public Health (Medicinal Cannabis) Regulation 2017
**Notice of Patient Commencement
(Patient-Class Prescriber)**

The Department of Health provides this form so that you may notify the Chief Executive as required under the *Public Health (Medicinal Cannabis) Regulation 2017* that a particular eligible patient's treatment with medicinal cannabis has commenced. **Notifications are to be made within 7 days of commencement.**

SECTION 1: PRESCRIBER DETAILS					
Full Name:				AHPRA Registration Number:	
SECTION 2: PATIENT DETAILS					
Full Name:				Date of Birth: DD/MM/YYYY	
Residential address:					
Date medicinal cannabis commenced: DD/MM/YYYY					
SECTION 3 - MEDICINAL CANNABIS PRODUCTS					
Please provide details of the proposed medicinal cannabis products:					
Product Name	THC (%)	CBD (%)	Dosage regimen mg /day (e.g. 250mg bd)	Form (e.g. oil, bud, capsules)	Route of administration
1.					
2.					
3.					

Notifications must be forwarded by **POST** or **FAX** to:

Chief Executive
Medicinal Cannabis Unit
Locked Bag 21
FORTITUDE VALLEY BC 4006
Fax: (07) 3328 9821

RTI REQUEST



Notification as a Patient-class Prescriber (PCP)

If completing the form by hand please use BLOCK LETTERS and ensure that details are legible.

1. Name (first name and family name)

Name of practice

Address

Suburb/Town

Post code

(This address must be where you undertake the activity from)

Telephone:

Fax:

Email:

Please tick your preferred contact method:

Telephone

Fax

Email

AHPRA registration number

PBS prescriber number

AHPRA registered specialty

2. As a PCP I will be prescribing for the following class of patients

- Persons experiencing chemotherapy induced nausea or vomiting
- Terminally ill persons being treated by a compliant palliative medicine specialist for symptoms associated with terminal illness
- Children with intractable (drug resistant) epilepsy
- Persons with multiple sclerosis experiencing spasticity

(Please note that if the medical condition/symptoms are different to the classes above then you are not able to prescribe under the PCP pathway)

3. As a PCP I will be prescribing the following product to the class of patient above:

- Cannabidiol product (CBD alone)
- 1:1 combination of delta-9-tetrahydrocannabinol (THC) and CBD
- Other combination THC/CBD product (please specify _____)
- THC only product

Product manufacturer / wholesaler _____

4. Therapeutic Goods Administration Approval

- I am an Authorised Prescriber under the TGA
- I am applying to become an Authorised Prescriber under the TGA



Notification as a Patient-class Prescriber (PCP)

I will use the Special Access Scheme, Category B, for my patients

If you are an Authorised Prescriber please provide details of the Ethics Committee that has approved the use of the product. (Note: The Ethics committee must be a Human Research Ethics Committee that has been constituted in accordance with NHMRC Ethics Committee guidelines. The letter of approval should be attached to this application, or forwarded as soon as possible)

Name of Committee: _____

HREC Approval Number: _____

Product(s) approved: _____

Indication: _____

Site: _____

Any conditions:

Expiry date of approval _____

Trial number (if appropriate) _____

5. Will you be engaging an agent (e.g. a pharmacist) to import/obtain product of your behalf?

- NO – Go to Question 6
- YES - specify the agent _____

6. Will you be engaging an agent to transport the product(s) on your behalf?

- NO – Go to Question 7
- YES – please specify _____

7. Will you be dispensing the product from your practice?


- NO – Go to Question 8
- YES –please complete a Medicinal Cannabis Management Plan and attach

8. Do you have a specific pharmacy that will be dispensing product(s) on your prescription?

- NO – patient will choose their own pharmacy (please provide details below)
- YES – please provide details below

Pharmacy Name: _____

Name of Pharmacist: _____





Notification as a Patient- class Prescriber (PCP)

Pharmacy Address:

Contact details: Phone

Fax

Email

Declaration:

I declare that there are no conditions, undertakings or other disciplinary actions imposed on my registration as a medical practitioner/nurse practitioner with the Australian Health Practitioner Regulation Agency, nor in any other jurisdictions, nor with any other authority, either currently or pending, that prohibit or restrict my ability to treat any person with any controlled drug (schedule 8).

I confirm that the information I have provided in this application is true and complete to the best of my knowledge.

Signed:

Date:

Privacy Statement:

The personal information and documents collected for the purpose of this application will be securely stored, and only accessible and used by authorised departmental persons in accordance with the Public Health (Medicinal Cannabis) Act 2016. If approved, the prescriber is also required to report further personal information relating to the patients' response to treatment to Queensland Health.

Queensland Health may be required to make enquiries of, and exchange personal information with, other State, Territory or Commonwealth entities regarding any matters relevant to this application. The department will not disclose any personal information provided with this application and supporting documents to any other third parties without your consent unless required or authorised by law.

The Information Privacy Act 2009 (Qld) sets out the rules for the collection and handling of personal information by Queensland Health. For information about how Queensland Health protects your personal information, or to learn about your right to access your own personal information, please see our website at www.health.qld.gov.au

Attachments – please specify

- Human Research Ethics Committee-Letter of Approval
- Medicinal Cannabis Management Plan

From: [Michael Carroll](#)
To: [Victoria Chalmers](#)
Cc: [Geoff Wallace](#); [Gregory Perry](#)
Subject: 13HEALTH script change for the Compassionate Access Scheme
Date: Friday, 25 August 2017 1:59:37 PM
Attachments: [image001.png](#)
[image002.png](#)
[image003.png](#)
[image004.png](#)
[image005.png](#)

Hi Victoria,

I work at the Centre for Children's Health Research and provide support to the Medicinal Cannabis Compassionate Access Scheme for children with severe refractory epilepsy. I was originally sending this message to Shelley Peardon but have since been redirected to you.

Our scheme commenced at the end of last year and 13HEALTH was the initial avenue for parents to express interest on behalf of their children. The scheme has now progressed to a point where some scripting provided to 13HEALTH is out of date, and parents no longer need to express interest via this avenue. We'd now like our 13HEALTH message to be updated to:

Information about the Medicinal Cannabis Compassionate Access Scheme for children with severe refractory epilepsy can be obtained by calling the Clinical Research Manager (Neurodevelopmental Disorders), Centre for Children's Health Research, Lady Cilento Children's Hospital, on 07 3069 7405.

I've CCed into this message Dr Geoff Wallace (the Lead Investigator on the scheme) and Greg Perry (Director of the Medicinal Cannabis Unit). We're not familiar with the scripting process so please let me know what other information or authorisations are required to make the update.

Kind regards,

Michael Carroll
Clinical Research Manager (Neurodevelopmental Disorders)

Children's Health Queensland Hospital and Health Service
Level 6 – Centre for Children's Health Research
Lady Cilento Children's Hospital
62 Graham Street, South Brisbane QLD 4101

T: 07 3069 7405 M:
E: Michael.Carroll@health.qld.gov.au
W: www.childrens.health.qld.gov.au



Children's Health Queensland

Service | Integrity | Courage | Innovation | Accountability

Queensland Health acknowledges the Traditional Owners of the land, and pays respect to Elders past, present and future.

From: Michael Carroll
To: Geoff Wallace; Honey Heussler; Andrew Hallahan; Gregory Perry; Rochelle Green; Sonya Stacey; Helen Irving; Melissa Fox; John Pearn [redacted]@uq.edu.au> [redacted]@uq.edu.au
Cc: Emily Milburn; John Pearn
Subject: Neurodevelopmental Disorders Steering Committee meeting minutes - 23/08/2017
Date: Friday, 25 August 2017 11:51:22 AM
Attachments: [image001.png](#)
[image002.png](#)
[image003.png](#)
[image004.png](#)
[image005.png](#)
[ND Steering Committee Meeting Minutes #16 - 23.08.17.pdf](#)
[CCRND Steering Committee Terms of Reference V1 25082017.doc](#)

Hi everyone,

Attached are the minutes from Wednesday's Neurodevelopmental Disorder Steering Committee meeting.

Also attached is a draft Terms of Reference which relates to re-aligning the committee from the CAS to our broader research centre. Let me know if you have any feedback and, as discussed at Wednesday's meeting, also consider whether current membership requires any change. Note that text in red font in that draft are items I'm seeking confirmation on. Please provide feedback by COB Friday September 7, after which a new draft will be produced.

Kind regards,

Michael Carroll

Clinical Research Manager (Neurodevelopmental Disorders)

Children's Health Queensland Hospital and Health Service
Level 6 – Centre for Children's Health Research
Lady Cilento Children's Hospital
62 Graham Street, South Brisbane QLD 4101

T: 07 3069 7405 M: [redacted]
E: Michael.Carroll@health.qld.gov.au
W: www.childrens.health.qld.gov.au



Children's Health Queensland

Service | Integrity | Courage | Innovation | Accountability

Queensland Health acknowledges the Traditional Owners of the land, and pays respect to Elders past, present and future.